[Immunosuppression after liver transplantation]

Area of Science:

• Immunology
• Pharmacology
• Transplantation Medicine

Background:

• Standard immunosuppression post-liver transplant (LT) involves calcineurin inhibitors (CNIs) like tacrolimus/cyclosporine, mycophenolate, and corticosteroids.
• Corticosteroids are typically withdrawn 6-12 months post-LT, unless the transplant is for autoimmune disease.
• Therapeutic drug monitoring of CNIs and mycophenolate is crucial for efficacy and safety.

Purpose of the Study:

• To review current immunosuppression protocols in liver transplantation.
• To discuss management strategies for rejection and adverse effects.
• To explore novel immunosuppressants and the future goal of achieving transplant tolerance.

Main Methods:

• Review of standard immunosuppressive agents and their monitoring.
• Description of first- and second-line treatments for rejection.
• Introduction of newer agents like mTOR inhibitors and their specific applications.

Main Results:

• CNIs combined with mycophenolate and corticosteroids form the standard of care.
• Antibodies targeting IL-2 receptors or lymphocytes can mitigate rejection and allow for reduced corticosteroid use.
• mTOR inhibitors offer an alternative with a different side-effect profile, beneficial in specific patient populations (e.g., renal impairment, cancer).

Conclusions:

• Optimizing immunosuppression aims to minimize adverse effects like kidney failure, metabolic complications, and infections to enhance patient and graft survival.
• The ultimate goal is to induce tolerance, potentially enabling cessation of prophylactic immunosuppression.
• Ongoing research into novel agents targeting specific pathways holds promise for future advancements in transplant care.